BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3765649)

  • 1. [Sequential determination of circulating immune complexes in ovarian tumors].
    Beaufort F; Auner H; Lahousen M
    Wien Med Wochenschr; 1986 Jul; 136(13):317-22. PubMed ID: 3765649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma.
    Dobryszycka W; Gerber J; Zuwała-Jagiełło J; Ujec M
    Arch Immunol Ther Exp (Warsz); 1991; 39(1-2):41-50. PubMed ID: 1725104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
    Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
    Gebauer G; Rieger M; Jäger W; Lang N
    Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
    Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
    Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
    Göcze P; Vahrson H
    Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
    Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
    Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases.
    Low JJ; Perrin LC; Crandon AJ; Hacker NF
    Cancer; 2000 Jul; 89(2):391-8. PubMed ID: 10918171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A sequential study of humoral factors in ovarian neoplasms.
    Gupta SC; Agarwal J; Singh PA; Mehdiratta NK; Keswani NK
    Indian J Pathol Microbiol; 1994 Jul; 37(3):319-26. PubMed ID: 7814065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The value of serum CA 125 for monitoring treatment of patients with ovarian cancer].
    Zaucha R; Kobierska A
    Przegl Lek; 1995; 52(2):51-3. PubMed ID: 7784616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is adjuvant radiotherapy in early stages (FIGO I-II) of epithelial ovarian cancer a treatment of the past?
    Skirnisdottir I; Nordqvist S; Sorbe B
    Oncol Rep; 2005 Aug; 14(2):521-9. PubMed ID: 16012740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.
    Blanchard P; Plantade A; Pagès C; Afchain P; Louvet C; Tournigand C; de Gramont A
    Gynecol Oncol; 2007 Jan; 104(1):41-5. PubMed ID: 16952391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
    Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
    Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomyxoma peritonei: a review of 23 cases.
    Wertheim I; Fleischhacker D; McLachlin CM; Rice LW; Berkowitz RS; Goff BA
    Obstet Gynecol; 1994 Jul; 84(1):17-21. PubMed ID: 8008316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulosa cell tumors of the ovary: prognostic factors and outcome.
    Malmström H; Högberg T; Risberg B; Simonsen E
    Gynecol Oncol; 1994 Jan; 52(1):50-5. PubMed ID: 8307501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Surgical therapy of ovarian carcinoma].
    Sevelda P
    Wien Med Wochenschr; 1996; 146(1-2):18-22. PubMed ID: 8835491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.